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Keypoints: 
1) In sick elderly patients, clusters of disease states are the ‘norm’, and 
recognising which morbidities should be prioritised is a key part of good 
geriatric clinical care. 
2) Medicine been so slow to adopt a holistic approach to care that 
recognises the benefits and efficiencies from prioritising possible health 
care interventions for the multi-morbid patient 
3) NICE has now formally recognised multi-morbidity as an important 
clinical issue which merits a clinical guideline. 
4) The guideline challenges physicians to adopt an approach that takes full 
and proper account of multi-morbidity.  
Text 
The Editors of Age and Aging of the British Geriatrics Society and the Journal of 
the American Geriatrics Society have agreed to publish periodic partner articles 
(editorials or commentaries) on clinical or policy issues of interest to our 
readers. Initially we plan to focus on recently released clinical guidelines or 
address major policy issues of relevance to the care of older persons. We 
intend to discuss these topics from our respective viewpoints, with the aim of 
broadening the dialogue and learning from differences in approach to health 
care adopted ‘across the pond’. These articles will be written by members of 
our editorial teams or solicited from experts on a given topic. 
In this pair of initial companion articles, we discuss our reactions to the recent 
National Institute for Health and Care Excellence (NICE) guideline ‘Multi-
morbidity: clinical assessment and management’1. The NICE guideline builds on 
previous work by the American Geriatrics Society Expert Panel on the Care of 
Older Adults, whose report on multi-morbidity was published in the Journal of 
the American Geriatrics Society in 20122. 
Multi-morbidity is a concept that is very familiar to geriatricians. In sick elderly 
patients, clusters of disease states are the ‘norm’, and recognising which 
morbidities should be prioritised is a key part of good geriatric clinical care. 
However despite the example of geriatrics, modern medicine has been slow to 
address the implications of multi-morbidity. The result is frail, multi-morbid 
elderly patients can be subjected to futile or even harmful investigations and 
treatments and, more commonly, are exposed to considerable treatment 
burdens. For example, applying NICE guidelines to a person with five common 
long-term conditions (previous MI, type 2 diabetes, osteoarthritis, COPD and 
depression) necessitates at least ten medicines, nine lifestyle modifications, 8-
10 primary care appointments per year, 8-30 psychosocial intervention 
appointments, and possibly smoking cessation and pulmonary rehabilitation3. 
So why has medicine been so slow to adopt a holistic approach to care that 
recognises the benefits and efficiencies from prioritising possible health care 
interventions for the multi-morbid patient? In many countries, including the 
UK, both primary and secondary care for long term conditions are organised 
around single disease management systems, supported by a raft of clinical 
guidelines which become operationalised into clinical treatment protocols that 
are largely irrelevant for the frail, multi-morbid older patient.  
In the US, there are additional problems with the systems of reimbursement 
(fee per service) which are perceived as resulting in over-use of ineffective (or 
even harmful) highly specialised costly interventions, while restricting access to 
more appropriate low technology holistic approaches to care – such as 
comprehensive geriatric assessment.  A more detailed US perspective on this is 
covered in the accompanying editorial in JAGS4. 
In this context the recent publication by the National Institute for Health and 
Care Excellence (NICE) of the guideline ‘Multi-morbidity: clinical assessment 
and management’1 is very welcome. Although NICE has authority only in 
England, their publications are generally seen as providing high-quality 
evidence based summaries that are highly influential in shaping clinical 
practice world-wide. In the UK in particular, service provision and clinical 
practice is strongly influenced by what NICE say. 
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That NICE has now formally recognised multi-morbidity as an important clinical 
issue which merits a clinical guideline is, in itself, a genuine step forward, if 
long over-due. It validates and gives licence for health care professionals to 
‘stray’ from stringent applications of single disease guidelines when confronted 
with a person with multi-morbidity. 
Multi-morbidity is conventionally defined as the presence of two or more LTCs. 
But this definition includes about one quarter of the population5 and for many 
of these people the application of single condition guidelines is wholly 
appropriate. A particular strength of the NICE guideline is the more clinically 
relevant approach taken to the recognition of intrusive multi-morbidity as 
identified by symptom complexes (e.g. frailty; chronic pain) and burdens (e.g. 
polypharmacy; need for multi-agency support). This pragmatic approach will 
be welcomed by clinicians and sets the scene for a range of recommendations 
relating to the purposeful identification of people who may benefit from an 
‘approach to care that takes account of multi-morbidity’, both 
opportunistically during routine health care encounters, and, more excitingly, 
proactively using systematic searching of primary care electronic health 
records. In effect, this is the pivot of the whole guideline as it anticipates more 
timely introduction of multi-morbidity management, before a point of crisis, 
and has the potential to stimulate new care models more closely aligned to the 
needs of people with multiple conditions.   
The guidelines give twenty recommendations that describe an ‘approach to 
care that takes account of multi-morbidity.’ The emphasis is strongly on 
empowerment of patients in clinical decision making. The aim is to give the 
recipients of care control over decisions and actions affecting their health. The 
difficulty is that this is a philosophy of clinical practice that should be integral 
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to the management all patients, multi-morbid or not. In a sense this is 
acknowledged within the guideline as the recommendations draw heavily on 
the sister guideline on patient experience in adult NHS services6 The 
component of the guideline that is more specific to people with multi-
morbidity incorporates the twin pillars of exploring existing disease and 
treatment burdens, and establishing future goals, values and priorities. These 
tasks will require a new type of clinical consultation, one that is considerably 
more discursive.  Encouragingly, health economic modelling conducted as part 
of the guideline indicated that this type of holistic assessment is likely to be 
highly cost-effective compared to usual care, though this conclusion was 
tempered by very limited outcome data. The new costs for a holistic care 
model were estimated at a modest £140 per person but the population cost 
will be high (many people have multi-morbidity) and the trick will be to chisel 
funding for this new approach out of existing processes of care that focus on 
single long term conditions, that will be forgone in favour of the new multi-
morbidity approach. With the current, over-stretched state of primary care 
services in many parts of the world (including the UK), implementation of the 
guideline will require careful orchestration and incentives, including some 
transitional funding. 
There are numerous potential benefits from the purposeful identification of 
intrusive multi-morbidity and the individualised, problem based approach 
described in the NICE guideline. These include better health care outcomes 
and the potential for more cost-effective use of resources. All too often 
medical decision-making currently fails to properly involve the patient in 
prioritising and selecting investigations and treatment. Atul Gawande’s book 
‘Being Mortal: Medicine and What Matters in the End’ highlighted how 
medicine has failed to grasp these issues at the end of life, giving examples 
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from the US of inappropriate and wasteful care that were not tailored to 
patients’ wishes and needs7 
Some teachings are timeless. Sir William Osler (1849-1919) once remarked: 
“The good physician treats the disease; the great physician treats the patient 
who has the disease.” The NICE guideline on multi-morbidity deserves to have 
international impact, with influence on both the purchasers and providers of 
health care. It challenges us to adopt an approach that takes full and proper 
account of multi-morbidity, and has the potential to re-empower us as holistic 
physicians and to release us from the constraints of contemporary protocol 
based medicine.  
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